Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Goodwin Biotechnology, a contract manufacturing organization, has completed the first phase of manufacturing of cancer diagnostic company Neogenix Oncology's monoclonal antibody, NPC-1C.
Subscribe to our email newsletter
The company has also delivered the GMP grade product to Neogenix in preparation for Phase I/II clinical trials planned for the first half of 2009.
NPC-1C is a novel monoclonal antibody intended for the treatment of advanced pancreatic cancer. It is also said to be the first of Neogenix monoclonal antibodies to enter development.
Philip Arlen, president and chief medical officer of Neogenix, said: “Completion of this phase of development with NPC-1C represents an important milestone for our company. The team at Goodwin has done an excellent job in delivering a high quality antibody that with FDA approval, will allow us to enter our Phase I/II trials.”